Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 69%, acquiring a total of 139,157 shares valued at approximately $88.23 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly exceeding analysts' expectations of $8.43, with a revenue of $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, representing an annualized dividend yield of 0.6%, with a payout ratio of 8.87%.

Acadian Asset Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 69.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 139,157 shares of the biopharmaceutical company's stock after purchasing an additional 56,816 shares during the period. Acadian Asset Management LLC owned about 0.13% of Regeneron Pharmaceuticals worth $88,233,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management increased its holdings in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Finally, Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on REGN shares. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Sanford C. Bernstein increased their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a report on Wednesday, August 27th. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Finally, BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $8.20 during mid-day trading on Friday, reaching $560.00. 602,540 shares of the company's stock were exchanged, compared to its average volume of 942,825. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $564.61 and a two-hundred day simple moving average of $579.66. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58. The company has a market cap of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals's revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.